Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024


News provided by

Research and Markets

23 Sep, 2014, 17:16 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, Sept. 23, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Continue Reading
This image opens in the lightbox
Research and Markets Logo. (PRNewsFoto/PR NEWSWIRE EUROPE)

Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Generally addressed as the marriage of an antibody with a toxic drug / chemotherapy drug, these conjugates are believed to be more efficient and effective in the treatment of a disease.

The ADC market is still in its infancy. At present, Adcetris and Kadcyla are the only two marketed drugs. However, there are several ADCs under development, with most of them being developed for oncological indication. Pharmaceutical companies are keen to add innovative molecules to their diminishing product pipelines and ADCs provide an attractive opportunity due to their novel nature.

Although the market now has presence of several large pharmaceutical companies, the technological capabilities for development of ADC still lies with a few technology providers. Seattle Genetics and ImmunoGen are amongst the pioneers in the field of ADC, with most pipeline ADCs using their technology. Most development to date has been carried under technology license agreements. However, we expect to see more co-development agreements in the future.

As more ADCs move from pipeline to the market, there is likely to be a further increase in investments in this area. Drug developers / venture capital firms are investing huge amount of money in biologics and it remains to be seen what proportion of this will be directed towards ADCs. The current market landscape will gradually evolve as large pharmaceutical companies look to gain competitive advantage in the ADC market. The future of the market is promising, though there are several challenges to meet.

The Antibody Drug Conjugates Market (2nd edition), 2014-2024 report provides an extensive study on this emerging field of therapeutics. The report covers various aspects, such as, advantages of antibody drug conjugates over traditional antibody therapeutics, the need for this new class of medicine, manufacturing challenges, key market drivers and upcoming opportunities.

One of the key objectives of this report is to understand the current and future state of the antibody drug conjugates market. This is done by analyzing:

  • Products currently available in the market and those under development (both clinical / pre-clinical),
  • Technology providers, and key cytotoxin, linker and conjugation technologies supporting the development of improved ADCs,
  • Partnerships which have taken place over the last five years covering product co-development, technology licensing and co-marketing,
  • Competitive landscape and inherent threats to growth in the short and long term,
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. ADC THERAPEUTICS: OVERVIEW AND BACKGROUND

5. ADC MARKET FORECAST, 2014 - 2024

6. MANUFACTURING OF ADCs

7. RECENT DEVELOPMENTS: FOCUS ON PARTNERSHIPS AND TECHNOLOGY EVOLUTION

8. PROFILES OF LEADING COMPANIES

9. SWOT ANALYSIS

10. INTERVIEW TRANSCRIPTS

11. CONCLUSIONS

12. APPENDIX 1: TABLES

13. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

Companies Mentioned:

  • 5AM Ventures
  • Abbott
  • AbbVie
  • Abgenix
  • AbGenomics
  • Abzena
  • Acceleris Capital
  • ADC Biotechnology
  • ADC Therapeutics
  • Adimab
  • Affinicon
  • Agensys
  • Albany Molecular Research, Inc. (AMRI)
  • Allozyne
  • Alpha Cancer Technologies
  • Alta Partners
  • Ambrx
  • Amerisource Bergen Corporation
  • Amgen
  • Amgen Ventures
  • Antitope
  • Apposite Capital
  • Aravis General Partner
  • Astellas Pharma
  • AstraZeneca
  • Avid Biologics
  • Baxter BioPharma Solutions
  • Bayer Healthcare
  • biOasis Technologies
  • Biocon
  • BioInvent International
  • Biotecnol
  • Biotest
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • BSP Pharmaceuticals
  • Cambrex Corporation
  • Cape Family Fund LLC
  • Carbogen Amcis
  • Cardinal Health, Inc
  • Catalent Pharma Solutions
  • Celldex Therapeutics
  • Celltrion
  • Celtic Therapeutics Holdings
  • Chugai Pharmaceuticals
  • CMEA Capital
  • CuraGen
  • CytomX Therapeutics
  • Cytovance Biologics LLC
  • Daiichi Sankyo
  • Dendreon Corporation
  • Dong-A Pharmaceutical
  • DSM Pharmaceuticals
  • Eli Lilly
  • Endo Pharmaceuticals
  • Endocyte
  • Esperance Pharmaceuticals
  • Fidelity Biosciences
  • Fujifilm Diosynth Biotechnologies
  • Genentech
  • Genmab
  • Glycotope
  • Goodwin Biotechnology
  • GSK
  • Hanwha Chemical
  • Harris and Harris Group
  • Heidelberg Pharma
  • Igenica
  • ImmunoGen
  • Immunomedics
  • Intellect Neurosciences
  • ISU Abxis
  • Janssen Cilag
  • Johnson & Johnson
  • Lansing Brown Investments LLC
  • Laureate Biopharmaceutical Services
  • Lilly Ventures
  • Lonza
  • MacroGenics
  • Maverick Capital
  • McKesson Corporation
  • Medarex
  • MedImmune
  • Medivation
  • Meiji Seika Pharma
  • Menarini Group
  • Merck
  • Merck KGaA
  • Mersana Therapeutics
  • Micromet
  • Millennium
  • Mylan
  • NBE Therapeutics
  • New Enterprise Associates
  • Nippon Kayaku
  • Novartis
  • Novasep
  • Oxford BioTherapeutics
  • Pfizer
  • Pfizer Venture Investments
  • Philochem
  • PhotoBiotics
  • Pierre Fabre Medicament Production
  • Piramal Healthcare Pharma Solutions
  • PlantForm Corporation
  • Polytherics
  • Progenics Pharmaceuticals
  • ProQuest Investments
  • PureTech Ventures
  • Redwood Bioscience
  • Rho Ventures
  • Roche
  • Sanofi Aventis
  • Seattle Genetics
  • Shanghai CP Guojian
  • Sigma Aldrich Fine Chemicals (SAFC)
  • Skyline Ventures
  • SocietàItalianaCorticosteroidiS.r.l
  • Spirogen
  • Stem CentRx
  • Sumitomo Pharmaceuticals
  • Sutro Biopharma
  • SV Life Sciences
  • SynAffix
  • Synthon
  • Takeda Pharmaceuticals
  • Tavistock Life Sciences
  • ThioLogics
  • TUBE Pharma
  • UCB Pharma
  • Ventana Medical Systems
  • Versant Ventures
  • VIVENTIA Biotechnologies
  • Watson Pharmaceuticals
  • Wilex
  • Wyeth
  • Zhejiang Medicine Co. Ltd. (ZMC)

For more information visit http://www.researchandmarkets.com/research/6vc6gm/antibody_drug

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.